Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
Open Access
- 23 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuroinflammation
- Vol. 17 (1), 1-8
- https://doi.org/10.1186/s12974-020-01773-w
Abstract
Longitudinally extensive transverse myelitis (LETM) is classically related to aquaporin (AQP4)-antibodies (Ab) neuromyelitis optica spectrum disorders (NMOSD) or more recently to myelin oligodendrocyte glycoprotein (MOG)-Ab associated disease. However, some patients remain negative for any diagnosis, despite a large work-up including AQP4-Ab and MOG-Ab. Data about natural history, disability outcome, and treatment are limited in this group of patients. We aimed to (1) describe clinical, biological, and radiological features of double seronegative LETM patients; (2) assess the clinical course and identify prognostic factors; and (3) assess the risk of recurrence, according to maintenance immunosuppressive therapy. Retrospective evaluation of patients with a first episode of LETM, tested negative for AQP-Ab and MOG-Ab, from the French nationwide observatory study NOMADMUS. Fifty-three patients (median age 38 years (range 16–80)) with double seronegative LETM were included. Median nadir EDSS at onset was 6.0 (1–8.5), associated to a median EDSS at last follow-up of 4.0 (0–8). Recurrence was observed in 24.5% of patients in the 18 following months, with a median time to first relapse of 5.7 months. The risk of recurrence was lower in the group of patients treated early with an immunosuppressive drug (2/22, 9%), in comparison with untreated patients (10/31, 32%). A first episode of a double seronegative LETM is associated to a severe outcome and a high rate of relapse in the following 18 months, suggesting that an early immunosuppressive treatment may be beneficial in that condition.This publication has 30 references indexed in Scilit:
- Longitudinally extensive transverse myelitisCurrent Opinion in Neurology, 2014
- The Role of 18F-FDG-PET and PET/CT in Patients with SarcoidosisAcademic Radiology, 2014
- Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis OpticaJAMA Neurology, 2014
- Cadre nosologique et stratégie diagnostique de la myélite aiguë transverse longitudinalement étendueRevue Neurologique, 2014
- Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 AntibodiesJAMA Neurology, 2013
- Aquaporin-4 antibody–negative neuromyelitis opticaNeurology, 2013
- Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive studyBMC Neurology, 2013
- Analysis of prognostic factors associated with longitudinally extensive transverse myelitisMultiple Sclerosis Journal, 2012
- Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitisAnnals of Neurology, 2006
- Proposed diagnostic criteria and nosology of acute transverse myelitisNeurology, 2002